Skip to main content
SpringerLink
Log in

Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system

  • Original Articles
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

The effects of medroxyprogesterone acetate (MPA) therapy on advanced or recurrent breast cancer and its influence on blood coagulation and the fibrinolytic system were compared among three different therapy regimens consisting of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) + MPA and CAF or MPA alone. A clinical response was observed in 42.9% (9/21) of the patients for CAF + MPA, 36.4% (8/22) for CAF and 23.8% (5/21) for MPA alone. No marked thrombosis or its prodromal condition was observed in any group. The effects on the test values for blood coagulation and the fibrinolytic system did not significantly change in the CAF group. However, both AT-III and protein C significantly increased above the normal ranges in the CAF + MPA and MPA groups. Increases in factor X, plasminogen, and α2-plasmin inhibitor/plasmin complex (PIC) and decreases in fibrinogen, tissue plasminogen activator, and D-dimer, were all observed in the MPA and CAF + MPA groups, especially in the MPA group, although these changes remained within the normal ranges. The data indicated that MPA has various influences on blood coagulation and the fibrinolytic system, but these changes did not suggest activation of the blood coagulation system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Department of Safety, Pharmaceutical Affairs Bureau, Japanese Ministry of Health & Welfare (1989) Administration of high-dose medroxyprogesterone acetate and severe thrombosis (in Japanese). Iyakuhin Fukusayo John No. 96, 1

  2. Japanese Breast Cancer Society (1992) Standards for assessment of the therapeutic effects in advanced or recurrent breast cancer patients (in Japanese). In: General rules for clinical and pathological recording of breast cancer. Kanehara Shuppan, Tokyo, pp 53–61

    Google Scholar 

  3. Japan Society for Cancer Therapy (1986) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy (in Japanese). Nippon Gann Chiryou Gakkaishi (J Jpn Soc Cancer Ther) 21:931–942

    Google Scholar 

  4. Tominaga T, Izuo M, Nomura Y, Kubo K, Abe O, Enomoto K, Takatani O (1982) Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: A dose response evaluartion (in Japanese with English abstract). Gan To Kagakuryoho (Jpn J Cancer Chemother) 9:1994–2004

    Google Scholar 

  5. Yoshida M, Murai H, Miura S (1985) Therapeutic effects of medroxyprogresterone acetate in recurrent or advanced breast cancer (in Japanese with English abstract). Gan To Kagakuryoho (Jpn J Cancer Chemother) 12:516–523

    Google Scholar 

  6. Tominaga T, Abe O, Ohshima A, Hayasaka H, Uchino J, Abe R, Enomoto K, Izuo M, Watanabe H, Takatani O, Yoshida M, Sakai K, Koyama H, Hattori T, Senoo T, Monden Y, Nomura Y (1994) Comparison of chemotherapy with or without medroxyprogesterone acctate for advanced or recurrent breast cancer. Eur J Cancer 30A:959–964

    Google Scholar 

  7. Lober J, Mouridsen HT, Rose C (1983) Oral or intramuscular treatment of advanced breast cancer with medroxyprogesterone acetate: A review. In: Campio L, Robustelli Della Cuna G, Taylor RW (eds) Role of medroxyprogesterone in endocrine-related tumors, vol. 2. Raven, New York, pp 105–114

    Google Scholar 

  8. Robustelli Della Cuna G, Pellegrini A (1984) Medroxyprogesterone acetate in combination with chemotherapy for advanced breast cancer: Update results and criticisms. In: Pellegrini A, Robustelli Della Cuna G, Pannuti F, Pouillart P, Jonat W (eds) Role of medroxyprogesterone in endocrine-related tumors, vol. 3. Raven, New York, pp 91–104

    Google Scholar 

  9. Department of Safety, Pharmaceutical Affairs Bureau, Japanese Ministry of Health & Welfare (1992) Occurrence of thrombosis during the administration of high-dose medroxyprogesterone acetate in patients with breast cancer and endometrial cancer (in Japanese). Iyakuhin Kenkyu 23(5):664–671

    Google Scholar 

  10. Bonsignori M, Rossi G, Sturba F, Cajozzo A, Abbadessa V, DeSandre G, Bassetto MA, Benini F, Bonetti A, Capelli MC, Falezza GC, Franccschi T, Molino A, Gibelli A, Rocchini GM, Luporini G, Beretta G, Fraschini P, Tabiadon D, Gambrosier P, Malacarne P, Bertusi M, Indelli M, Rausa L, Palmeri S, Robustelli Della Cuna G, Bernardo A, Bernardo G, Schieppati G, Navassa G, Battaglia A, Militello S, Perbellini A, Pollini C, Sacchetti G, Sani V, Soldati M, MPA Hematology Italian Cooperative Group (1986) Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. Chemioterapia 5:134–139

    Google Scholar 

  11. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group (JABCSG & JCOG) (1993) Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Jpn J Cancer Res 84:455–461

    Google Scholar 

  12. Brema F, Queirolo MA, Canobbio L, Bruzzi P, Puntoni R, Campora E, Rosso R (1981) Hematologic parameters during treatment with high-dose medroxyprogesterone acetate. Tumori 67:125–128

    Google Scholar 

  13. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T (1990) The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients. Jpn J Surg 20:665–670

    Google Scholar 

  14. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T (1991) Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer. Jpn J Cancer Res 82:420–425

    Google Scholar 

  15. Okamoto K, Takaki A, Kuroda Y, Osato K, Mitsuyama S, Nakamura Y, Shirakusa T, Murakami F, Nishikata F, Yasunaga T, Yamanouchi A, Ikeda S, Egami T, Mori A, Ohe H, Yasunami Y (1991) The protein C, the protein S and the anithrombin III levels prior to and during oral administration of medroxyprogesterone acetate as adjuvant therapy in stage III breast cancers (in Japanese with English abstract). Gan no Rinsho (Jpn J Cancer Clin) 37:1749–1753

    Google Scholar 

  16. Sawaguchi K, Nozaki S, Hojo T, Yabushita H, Noguchi M, Nakanishi M (1991) Effect of high-dose medroxyprogesterone acetate (HD-MPA) on coagulative and fibrinolytic factors in patients with endometrial cancer (in Japanese with English abstract). Nippon Gan Chiryo Gakkaishi (J Jpn Soc Cancer Ther) 26:1401–1405

    Google Scholar 

  17. Ishizaki T, Itoh R, Yasuda J, Yamamoto T, Okada K (1990) Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers (in Japanese with English abstract). Gan To Kagakuryoho (Jpn J Cancer Chemother) 19:837–842

    Google Scholar 

  18. Yamamoto H, Noguchi S, Inaji H, Imaoka S, Koyama H, Iwanaga T (1991) Relationship between high-dose medroxyprogesterone acetate (MPA) and thromboembolic diseases in patients with breast cancer. Nippon Gan Chinyogakkaishi (J Jpn Soc Cancer Ther) 26:189

    Google Scholar 

  19. Yamamoto H, Noguchi S, Inaji H, Koyama H, Imaoka S (1991) Hormone therapy and hemostatic mechanism in breast cancer (in Japanese). Seijinbyo (Adult Diseases) 31:87–95

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, Keio University, Japan

    Osahiko Abe (Chairman)

  2. First Department of Surgery, Sapporo Medical College, Japan

    Kazuaki Asaishi (Protocol committee member)

  3. Second Department of Surgery, School of Medicine, Gunma University, Japan

    Masaru Izuo (Protocol committee member)

  4. Department of Surgery, School of Medicine, Keio University, Japan

    Kohji Enomoto (Protocol committee member)

  5. Department of Surgery, The Center for Adult Diseases, Osaka

    Hiroki Koyama (Protocol committee member)

  6. Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan

    Takeshi Tominaga (Protocol committee member)

  7. Department of Breast Surgery, National Kyushu Cancer Center Hospital, Japan

    Yasuo Nomura (Protocol committee member)

  8. Department of Cancer Prevention, Osaka Cancer Prevention and Detection Center, Japan

    Akira Ohshima (Controller)

  9. First Department of Internal Medicine, Tokyo Medical and Dental University School of Medicine, Japan

    Nobuo Aoki (Advisor)

  10. Department of Hematology, Toranomon Hospital, Japan

    Toshiyasu Tsukada (Advisor)

Authors
  1. Osahiko Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuaki Asaishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaru Izuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kohji Enomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroki Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuo Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nobuo Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshiyasu Tsukada
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Study Group for the Chemo-endocrine Therapy of MPA for Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abe, O., Asaishi, K., Izuo, M. et al. Effects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. Surg Today 25, 701–710 (1995). https://doi.org/10.1007/BF00311486

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00311486

Key Words

Search

Navigation